LOS ANGELES, CA--(Marketwired - Jan 10, 2014) - SK3 Group, Inc (OTC Pink: SKTO) is pleased to announce that it has completed the licensing agreements between Berkeley Bio-Organic Research Laboratories, LLC and its managed wholesale collectives to produce non-psychoactive mixed cannabinoid carboxylates (Dharmanol™). The licensing agreement covers the proprietary methods developed by Berkeley Bio -- known as cryo-extraction -- used to extract the cannabinoids and preserve them in their non-psychoactive state.
"We are happy to have put together more of the elements necessary to fill the large demand anticipated for our Dharmanol™ product line," said Artemus Mayor, President of SK3 Group. "Dr. Charles Apel and David Hoye have developed a unique technique for extracting the non-psychoactive but effective components of cannabis that we believe will prove to be the key to bringing an entirely new dimension to the field of nutritional supplements in the United States and greater access to the beneficial effects of medical marijuana."
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.